Aquestive Therapeutics, Inc. (AQST) — Financial statements
Income statement, balance sheet, and cash flow for Aquestive Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 45↓22.6% | 58↑13.8% | 51↑6.1% | 48↓6.2% | 51 | |
| Cost of Revenue | 17↓4.0% | 18↓14.2% | 21↑7.5% | 19↑29.3% | 15 | |
| Gross Profit | 27↓31.0% | 40↑33.4% | 30↑5.2% | 28↓21.1% | 36 | |
| Operating Expenses | ||||||
| R&D Expenses | 17↓15.2% | 20↑54.8% | 13↓25.0% | 17↑2.5% | 17 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 80↑59.1% | 50↑58.0% | 32↓40.0% | 53↓1.1% | 53 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 97↑37.7% | 70↑57.1% | 45↓36.3% | 70↓0.2% | 71 | |
| Total Costs & Expenses | 114↑29.3% | 88↑34.5% | 66↓26.8% | 90↑5.0% | 86 | |
| Operating Results | ||||||
| Operating Income | -70↓126.4% | -31↓103.8% | -15↑64.1% | -42↓21.3% | -35 | |
| Depreciation & Amortization | 0.56↓22.1% | 0.72↓46.6% | 1↓43.7% | 2↓19.5% | 3 | |
| EBITDA | -69↓159.6% | -27↓2351.8% | 1↑103.0% | -40↑12.3% | -45 | |
| EBIT | -70↓154.8% | -27↓16669.3% | -0.16↑99.6% | -42↑12.7% | -48 | |
| Interest & Other Income | ||||||
| Net Interest Income | -17↓27.8% | -13↓251.0% | 9↑171.8% | -12↑44.0% | -22 | |
| Interest Income | 0.00↓100.0% | 3↓78.9% | 16↑16385.9% | 0.10↓76.6% | 0.42 | |
| Interest Expense | 17↑1.7% | 17↑125.4% | 7↓40.0% | 12↓44.6% | 22 | |
| Non-Operating Income | 0.00↑100.0% | -3↑77.0% | -15↓14989.9% | -0.10↓100.7% | 13 | |
| Other Income / Expenses | -14↓5.6% | -13↓278.9% | 7↑160.6% | -12↑65.6% | -36 | |
| Income Before Tax | -84↓89.8% | -44↓479.0% | -8↑86.0% | -54↑22.9% | -71 | |
| Income Tax Expense | 0.00↑100.0% | -0.01↓105.7% | 0.25 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -84↓89.8% | -44↓460.8% | -8↑85.5% | -54↑22.9% | -71 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -84↓89.8% | -44↓460.8% | -8↑85.5% | -54↑22.9% | -71 | |
| Bottom-Line Net Income | -84↓89.8% | -44↓460.8% | -8↑85.5% | -54↑22.9% | -71 | |
| EPS (Basic) | -0.76↓49.0% | -0.51↓292.3% | -0.13↑88.4% | -1.12↑39.5% | -1.85 | |
| EPS (Diluted) | -0.76↓49.0% | -0.51↓292.3% | -0.13↑88.4% | -1.12↑39.5% | -1.85 | |
| Weighted Average Shares | 122↑40.6% | 87↑41.6% | 61↑25.7% | 49↑28.0% | 38 | |
| Weighted Average Diluted Shares | 122↑40.6% | 87↑41.6% | 61↑25.7% | 49↑28.0% | 38 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.